Screener
Discontinued — last reported Q4 '22
CapEx at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Rigel Pharmaceuticals’s 10-K, filed March 5, 2024.
- Filed
- Mar 5, 2024
- Fiscal year
- FY2023
- Accession
- 0001558370-24-002475
| Line item | Year Ended December 31, 2023 | Year Ended December 31, 2022 | Year Ended December 31, 2021 |
|---|---|---|---|
| Purchases of short-term investments | (31,206) | (28,894) | (141,459) |
| Purchases of intangible asset | (15,000) | — | |
| Proceeds from sale of property and equipment | 259 | 893 | — |
| Purchases of property and equipment | — | (450) | (627) |
| Net cash (used in) provided by investing activities | (4,297) | 72,777 | (80,036) |
| Financing activities | |||
| Net proceeds from term loan financing | 19,950 | 19,542 | — |
| Net proceeds from issuances of common stock upon exercise of options and participation in Purchase Plan | 1,049 | 2,124 | 4,775 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Rigel Pharmaceuticals's capex?
- Rigel Pharmaceuticals (RIGL) reported capex of $73K in Q4 2022.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Rigel Pharmaceuticals's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude